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Abstract. Type 2 diabetes is a leading cause of death and morbidity and is a health 
priority in Australia.  This randomised controlled trial will explore whether remote 
access to clinical care, supported by telehealth technologies over high speed 
broadband, leads to improved diabetes control in a way that benefits patients, 
carers and clinicians and improves the overall health system. People in the 
intervention arm of the trial will receive additional diabetes care from a care 
coordinator nurse via an in-home broadband communication device that can 
capture clinical measures, provide regular health assessments and videoconference 
with other health professionals when required. Patients in the control arm of the 
trial will receive usual care from their GP and participate in the clinical 
measurement and quality of life components of the evaluation. The trial evaluation 
will include biomedical, psychological, self-management and quality of life 
measures. Data on utilisation rates and satisfaction with the technology will be 
collected and cost -effectiveness analyses undertaken. The role of this technology 
in health care reform will be explored. 
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Introduction 
The increasing prevalence of type 2 diabetes is a phenomenon which has created 
significant challenges for many countries including Australia. The estimated worldwide 
prevalence of diabetes among adults was 285 million in 2010 and this value is 
predicted to rise to around 439 million by 2030 [1]. In Australia over 818,200 people 
(4% of the population) have been diagnosed with diabetes; 10% have type 1 and 88% 
have type 2 diabetes (2% reported they did not know the type) [2] with an estimated 
275 new cases of diabetes being diagnosed every day [3].   Type 1 diabetes, which 
accounts for the minority of cases, is primarily due to a combination of genetic, 
biological and environmental factors.  The substantial increase in diabetes rates overall 
are in type 2 diabetes and although there is a strong genetic predisposition, the risk of 
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 type 2 diabetes is greatly increased when associated with lifestyle factors such as high 
blood pressure, overweight or obesity, insufficient physical activity and poor diet [4].  
Diabetes is a chronic condition which accounts for 5% of the total burden of 
disease [5] and is the sixth leading cause of deaths in Australia [6].  Studies have 
shown that poor glycaemic control, as measured by glycated haemoglobin (HbA1c), 
significantly increases the risk of diabetes-related complications such as microvascular 
complications, neuropathy, retinopathy, nephropathy, myocardial infarction and stroke 
[7,8]. Indeed, chronic and preventable illness has reached the point where the 
Australian health system can no longer sustain the level of burden of disease [9-11]. 
Research consistently supports the notion that targeting populations at greater risk of 
chronic disease results in longer term savings to the health system. Findings from 
national and international research suggest that countries with stronger primary care 
systems and effective management of chronic disease systemic factors have better 
health outcomes and lower costs [9,12] . 
Diabetes self-management which involves educating individuals to manage their 
diabetes is a key component of effective diabetes care.  The goals of diabetes education 
are to optimize metabolic control, improve compliance with medical regimens, prevent 
acute and chronic complications and enhance quality of life.  A systematic review of 
interventions targeting diabetes reported that active patient monitoring and 
encouragement of self-management behaviours positively impacted on disease 
management in the short term [13]. However the delivery of ongoing support to the 
growing number of people living with chronic conditions such as diabetes cannot be 
solved solely by conventional methods; other more cost effective alternatives that will 
reach a large number of individuals, particularly those who have poor access to health 
services due to geographical, financial and other barriers, should be considered.   
The adoption of telehealth/telemedicine [2] offers a potential solution to chronic 
disease management as it can provide support to help a person manage their condition 
at a time and place which is convenient for them. The World Health Organisation’s 
[14] broad definition states that telemedicine is ‘The delivery of health care services, 
where distance is a critical factor, by all health care professionals using information and 
communication technologies for the exchange of valid information for diagnosis, 
treatment and prevention of disease and injuries, research and evaluation, and for the 
continuing education of health care providers’. Research from large scale programs 
have shown that the use of telehealth technologies combined with a care coordination 
model of care can be effective in helping people manage their chronic health condition.  
A US study of over 17,000 patients enrolled in a home telehealth program reported a 
20% reduction in hospital admissions and 25% reduction in bed days of care [15].  In 
the UK an evaluation of the Whole System Demonstrator telehealth/telecare trial 
reported that participation in the trial had a positive impact on patients’ quality of life, 
independence and empowerment in relation to managing their chronic condition [16].  
The study also highlighted the importance of patient and clinician engagement in this 
approach to care management.    
The cited benefits of telehealth such as greater access to healthcare services, 
improved health outcomes and more cost effective service delivery suggest that 
telehealth has the potential to change the delivery of healthcare [14].  Nevertheless 
there are a number of factors which can impact on its widespread adoption.   Whilst the 
dearth of robust evidence for the value of telehealth remains a barrier [17-19], other 
factors including additional work loads and preference for the traditional approach of 
care have implications for the uptake of telehealth [20].  In addition, researchers have 
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 identified lack of appropriate equipment, poor technology infrastructure and unreliable 
internet access particularly outside metropolitan areas as impacting on extensive usage 
of telehealth technology [21].  However the publication of standards for General 
Practitioners (GPs) offering video consultations [22] and the introduction of financial 
incentives in the form of new Medicare Benefits Schedule (MBS) items [23] reflect 
moves from the Australian Government to encourage nationwide implementation of 
telehealth.  Furthermore the National E-health Strategy [24] and the National Digital 
Economy Strategy [25] both make specific reference to the implementation of 
telehealth solutions to enable a safer, higher quality, more equitable and sustainable 
health system. 
This study attempts to address the need to support people with poorly controlled 
type 2 diabetes by examining the feasibility of using telehealth within a fully integrated 
case management model.  The model of service delivery includes telehealth monitoring 
of key diabetes health indicators, home management, education and support. These 
services will be primarily delivered by care coordinator nurses dedicated to the trial, 
but will also allow for video consultations with GPs and remote group education with 
Allied Health Professionals.  The trial participants are located in a regional area of 
Queensland (Australia) which is serviced by high speed broadband (National 
Broadband Network (NBN)); therefore a key objective of the trial will be to determine 
the ways in which the additional capacity of the broadband infrastructure can be 
utilised to deliver patient care. 
1. Aims 
This paper presents the study protocol for a randomised controlled trial (RCT) of a 
diabetes in-home telehealth monitoring system.  The trial will explore whether remote 
access to clinical care, supported by telehealth technologies over high speed broadband, 
leads to improved diabetes control in a way that benefits patients, carers and clinicians, 
and improves the overall health system.   
The primary aim is to investigate the effects of the diabetes in-home monitoring on 
health outcomes. Secondary aims include: to assess improvements in the experience of 
care for patients, their carers and clinicians; to determine if there is an improvement in 
primary care capacity and the integration of care; to assess any improvement in the 
efficiency of health service utilization (i.e. to determine the cost-effectiveness of the 
intervention compared with the control group); and to determine the utilization of the 
high speed broadband.   
2. Methods/study design 
The study is a two-arm prospective RCT in which a total of up to 210 adults with type 
2 diabetes will be randomised to either the intervention (diabetes program) or to the 
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 2.1. Study sample 
Eligibility criteria include: patient diagnosed with type 2 diabetes with a recorded 
HbA1c of ≥ 7.5% in the previous 12 months; aged 18 years or over; living within the 
NBN footprint in their own home (i.e. not in residential care) and receiving primary 
care from a general practice.  Patients are excluded if they are: diagnosed with severe 
unstable comorbidities with likely poor prognosis within 12 months; pregnant or 
diagnosed with gestational diabetes; diagnosed with dementia or intellectual and 
mental impairment (that would preclude use of technology); diagnosed with cancer 
(except non-melanotic skin cancer); have severe vision impairment (if deemed unable 
to use technology); suffer from chronic kidney disease  and on dialysis or likely to be 
on dialysis within the timeframe of the trial; have a primary language other than 
English or currently enrolled in another intervention trial.  
It is anticipated that complete data will be collected for 210 participants.  With 210 
completing participants, we will be able to detect intervention effects over usual care 
effects of at least a 0.4% reduction in HbA1c with 80% power and type I error of 5% 
(two-tailed).  The calculations for HbA1c were based on standard deviations of change 
in HbA1c of 1% in both groups.  An effect size of 0.4% in HbA1c was chosen for the 
sample size calculations based on Toobert et al., [26], who calculated that a change of 
0.4% translates into a clinically substantial 14% reduction in risk of diabetes 
complications based on the analysis of the UK Prospective Diabetes Study in patients 
with type 2 diabetes [27]. 
 
2.2. Recruitment procedures 
Our primary recruitment method is via general practices.  A range of other strategies 
are also being adopted to support this method including, active recruitment which 
comprises of liaison with diabetes clinics at hospital and community health, official 
trial launch and participation at technology-related community events within targeted 
areas.  Passive recruitment methods include:  leaflets and posters in general practices 
and other allied health professional practices, display equipment at Lifetec and 
pharmacies, advertisement in local newspapers, GP targeted e-publications and 
newsletters. Individuals who are interested in participating and meet the inclusion 
criteria are sent information about the trial and consent forms. After signing the consent 
forms patients are randomised to control or intervention arms of the trial.    
 
2.3. Study arms 
Patients in the control arm of the trial will receive usual care from their GP and 
participate in the clinical measurement and health assessment components of the 
evaluation. 
People in the intervention arm of the trial will receive online diabetes care from a 
care coordinator nurse via an in-home broadband monitoring and communication 
device that can capture clinical measures, provide regular health assessments and 
videoconference with other health professionals when required. The GPs will continue 
to manage their patients’ care in partnership with the care coordinator nurse, and they 
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 will together formulate a care plan consistent with the RACGP/ Diabetes Australia type 
2 diabetes guidelines [28] for each patient. The intervention period is 12 months. 
The intervention will enable the patient to remain in their own home while 
receiving clinical care from health professionals. The usual clinical relationships 
between the patient, GP and other health professionals continues, with agreed protocols 
for when the GP is to be contacted by the trial care coordinator nurse for both routine 
and non-routine encounters. 
Each care plan developed will include frequency for remote monitoring of clinical 
measures and patient health assessments and protocols for managing changes in the 
clinical status of the patient. For participants in the intervention arm, this program will 
include the following components, the results of which are delivered to the care 
coordinator nurse via the high speed internet connection: 
 
 regular blood pressure monitoring 
 regular blood glucose monitoring 
 participation in monitored online health questionnaires to reinforce diabetes 
self-management and assist early detection of complications 
 participation in clinical videoconferencing sessions, as required, with care 
coordinator nurse and GP. 
 
The monitoring system the patient will use is based around a tablet computer 
operated with touchscreen prompts. The blood pressure and blood glucose readings 
will be sent from the measuring devices to the monitoring software using Bluetooth 
technology.  The care coordinator nurse will provide in-home training in the use of 
devices for each participant, according to their needs, to ensure their comfort and 
optimal use of technology.   
  The care coordinator nurse will view patient results daily and respond 
appropriately to results that are outside set parameters i.e. they will contact the patient 
to ascertain if results are due to an urgent medical problem, equipment failure, incorrect 
measuring technique or other factor. The care coordinator nurse will contact the GP or 
appropriate health professional, if required. Parameters will be set individually to 
account for participants’ clinical situations. Trial nursing protocols will be prepared to 
allow all clinical staff to respond consistently. 
The care coordinator nurse will make regular contact with the patient, either by 
videoconference, telephone or home visit.  The capability for case conferencing via 
videoconference between the nurse and the patient’s GP will be available to ensure 
appropriate team-based clinical care. Communication between GP and care coordinator 
nurse will consist of: 
 
 initial care-planning session 
 regular emailed reports, the frequency of which are determined by the care 
coordinator’s assessment of patient risk (monthly – quarterly) 
 videoconferenced sessions to resolve emerging clinical complications 
 telephone contact as required. 
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 2.4. Randomisation 
The study design is according to the recommendations of the CONSORT statement for 
randomised trials of non-pharmacologic treatment [29]. Randomisation occurs after 
eligibility is determined and the patient has given consent.  Arm allocation is conducted 
using simple randomisation procedures (computerised random numbers) with the 
participant as the unit of randomisation. The trial manager will be contacted by the care 
coordinator nurse to allocate them into either the intervention or control group. The 
trial manager will not be given the location, identity or clinical status of the person.  
The care coordinator nurse will then advise the patient of which group they are in and 
arrange a visit for baseline assessment for both groups and installation of the health 
monitor for intervention patients.  
3. Findings/outcome measures 
The trial evaluation will include biomedical, psychological, self-management and 
quality of life measures. Data on utilisation rates and satisfaction with the technology 
will be collected and cost effectiveness analyses undertaken.  Patient data will be 
collected by clinicians (GP and care coordinator nurse) at baseline and repeated as 
follows: 
 
Table 1. Frequency of clinical outcome measures collected by clinicians (care coordinator nurse and GP) 
during trial 
Data Frequency 
HbA1c 3 monthly 
Cholesterol 12 months 
Renal Function 12 months 
Blood pressure – systolic and diastolic 3 monthly 
Weight monthly 
Waist circumference monthly 
 
Clinical record audit data to identify diabetes complications will be collected by 
practice nurses and care coordinator nurse at the conclusion of the trial period.  A 
complication will be recorded if the patient experiences a new episode of any of the 
following during the trial period: 
 
 death due to diabetes 
 hospital admission due to diabetes 
 renal disease  
 eye disease 
 vascular disease 
 neurological disease. 
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 Patient surveys will be undertaken at baseline (time 1), six months (time 2) and 12 
months (time 3) and scores recorded for: 
 
 quality of  life (SF12) 
 patient assessment of chronic illness care (PACIC)  
 clinical depression and mental health (Kessler Psychological Distress Scale). 
4. Data analyses 
Control and intervention patient clinical measures and survey responses will be 
compared using mean values and independent t-tests for each indicator at baseline, 
intervals and conclusion of trial.  Similar analyses will be conducted with clinical 
record audit data to compare the number of complications in the intervention and 
control groups.  The utilisation of the technology will be assessed by monitoring the 
number of videoconferenced and face-to-face interactions between the patients and 
their GP, care coordinator nurse, other allied health and specialists.  
Detailed economic data will be collected throughout the trial to enable a 
comprehensive evaluation of the intervention's efficiency when compared to routine 
care. Data on health care utilization will be obtained from participants at times 1, 2 and 
3, GP records (for primary care services) and from Queensland Health (for admissions 
to public hospitals). Standard costs will be applied to all health care utilization (e.g. 
Medicare Item numbers will be mapped to MBS costs, and Australian-Revised 
Diagnostic Related Groups for hospital admission costs). The intervention arm will 
also incur the costs of the intervention including set-up costs that will be annuitized 
(e.g. home monitors) and operating costs.  
Cost-utility analyses will be undertaken from the perspective of direct health care 
costs to the government.  The analyses will be a ‘within trial' analysis and a modelled 
analysis over the rest of life.   Quality of life (SF-12) scores will be converted to utility 
weights using the SF-6D algorithm [30] for the calculation of quality-adjusted life 
years (QALYs) – the primary health outcome measure for the economic evaluation. 
The incremental costs and QALYs will be calculated as the differences between 
participants in the intervention and routine care groups. The resulting incremental cost-
utility ratio will provide a measure of the relative value for money of the intervention 
using the additional cost per QALY gained. One-way and probabilistic sensitivity 
analyses will be undertaken for all parameters with uncertainty and/or variability [31]. 
5. Conclusions 
The potential benefits of the trial for the wider community relate to the increasing 
prevalence of type 2 diabetes in Australia, which is putting additional strain on the 
health care system to provide primary and secondary care. New methods of delivering 
care such as this remote model will give patients access to services regardless of their 
locality. The research will test whether on-line monitoring of patients is not only 
effective in improving their diabetes, but whether it is feasible and acceptable to the 
patients and their health professionals. It provides an opportunity for new technology to 
be tested in a real setting, and for recommendations about its use to be made for 
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 subsequent technological applications.  The benefits for the participants relate mainly 
to improved access to diabetes education and help with self-management of their 
condition, and earlier detection of changes in their health status. Teamwork between 
patient, care coordinator nurse and GP is facilitated by the technology and will improve 
the continuity of care.  
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